Safety and efficacy of the therapy with CD4 + CD25highCD127 ‐T regulatory cells: When paediatric patient becomes adult
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Marta Bandura und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Diabetology and Endocrinology, Medical University of Gdańsk, Gdańsk, Poland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, T-Lymphocytes, Regulatory, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agencja Badań Medycznych.
Abstract (Originalsprache)
Aim
CD4 + CD25highCD127 ‐T regulatory cells (Tregs) remain a drug candidate for immunotherapy of type 1 diabetes. We completed three trials testing Tregs in recently diagnosed type 1 diabetes children. Here, we looked for long‐term safety and efficacy aspects important in the authorisation of this therapy. Materials and methods We re‐examined 51 participants exposed to Treg therapy between 7.5 and 12 years prior to assessment. Based on previous assignments, we assessed the following subgroups treated with Tregs and anti‐ CD20 antibody (Tregs+ antiCD20 , N = 9), with 1 or 2 doses of Tregs only (Tregs 1 dose, N = 10 and Tregs 2 doses, N = 8). The exposed participants were compared with those who received standard of care therapy ( SoC control, N = 24) as part of previous studies. The patients underwent diabetes‐oriented tests as well as non‐ to minimal invasive evaluation of the anatomy and function of the eye, micro‐ and microcirculation, endocrine system, genitourinary tract and fertility, kidney and liver profiles, detailed biochemistry lab tests and safety screening. Over 700 variables were analysed.
Results
Tregs+ antiCD20 group was superior to SoC control group in terms of C‐peptide secretion in mixed‐meal tolerance test, the time of insulin independence and remission. No clinically relevant between‐groups differences were found in other performed examinations. Importantly, no severe adverse effects including tumors or deaths were reported.
Conclusions
We confirmed the long‐term safety and efficacy of the therapy. Due to the superior efficacy profile, the combined treatment with Tregs and antiCD20 antibody should be considered as a routine therapy for recent‐onset type 1 diabetes patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Diabetology and Endocrinology, Medical University of Gdańsk, Gdańsk, Poland.
- Department of Medical Immunology, Medical University of Gdańsk, Gdańsk, Poland.
- Poltreg S.A., Gdańsk, Poland.
- Department of Family Medicine, Medical University of Gdańsk, Gdańsk, Poland.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
- Department of Ophthalmology, Medical University of Gdansk, Gdańsk, Poland.
ORCID-Profile: Piotr Trzonkowski
Förderung
- Agencja Badań Medycznych
Zitieren
APA
Bandura, M., Piotrowska-Mieczkowska, M., Hennig, M., Gliwiński, M., Wołoszyn-Durkiewicz, A., Schoenhoff, J., Dybowska, M., Alska, A., Gutknecht, P., Trzeciak, B., Stefańska, K., Glasner, P., Hellmann, M., Burzyński, J., Michalak, A., Siebert, J., Iwaszkiewicz-Grześ, D., Myśliwiec, M., & Trzonkowski, P. (2026). Safety and efficacy of the therapy with CD4 + CD25highCD127 ‐T regulatory cells: When paediatric patient becomes adult. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70330
Vancouver
Bandura M, Piotrowska-Mieczkowska M, Hennig M, Gliwiński M, Wołoszyn-Durkiewicz A, Schoenhoff J, et al. Safety and efficacy of the therapy with CD4 + CD25highCD127 ‐T regulatory cells: When paediatric patient becomes adult. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70330
BibTeX
@article{Bandura2026,
author = {Bandura, Marta and Piotrowska-Mieczkowska, Magdalena and Hennig, Matylda and Gliwiński, Mateusz and Wołoszyn-Durkiewicz, Anna and Schoenhoff, Julia and Dybowska, Milena and Alska, Anna and Gutknecht, Piotr and Trzeciak, Bartosz and Stefańska, Katarzyna and Glasner, Paulina and Hellmann, Marcin and Burzyński, Jacek and Michalak, Arkadiusz and Siebert, Janusz and Iwaszkiewicz-Grześ, Dorota and Myśliwiec, Małgorzata and Trzonkowski, Piotr},
title = {Safety and efficacy of the therapy with CD4 + CD25highCD127 ‐T regulatory cells: When paediatric patient becomes adult},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70330}
}
EUVIMED